Base editing marches on the clinic
By Michael Eisenstein,
Nature
| 05. 09. 2022
This year could see the first trials of therapies employing base editing that introduce precise single-nucleotide changes into patient genomes.
Two companies, Beam Therapeutics and Verve Therapeutics, are leading the charge of base editing therapies to the clinic. Last November, Beam got the green light from the US Food and Drug Administration (FDA) for its upcoming BEACON-101 trial that will use base editing to restore expression of fetal globin in bone marrow stem cells. In parallel, Verve is preparing to embark on an in vivo base editing trial to treat patients who have experienced a heart attack and have abnormally high cholesterol levels by targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene, after obtaining promising results from preclinical work in rodents and non-human primates. “We’re optimistic about dosing our first patients in the second half of this year,” says Verve CEO and co-founder Sekar Kathiresan. The rapid progress of base editing programs is attracting interest from major pharmaceutical companies: in January, Beam entered a collaboration with Pfizer that could net the company up to $1.3 billion.
Beam’s rapid progress to the clinic — using technology developed just six years ago — has been built on the shoulders...
Related Articles
By Editorial Staff, The Lancet | 07.20.2024
Image by DrKontogianniIVF from Wikimedia Commons
Despite major advances in securing sexual and reproductive rights globally, one aspect is continually neglected: infertility. Evolving gender norms and financial precariousness have led to delayed childbearing, which increases infertility in both males and...
By Mesha Maren , Salon | 07.20.2024
By Alcott Wei, South China Morning Post | 07.13.2024
China has banned all clinical research involving germline genome editing under a newly released ethics guideline.
Germline gene engineering relates to altering the DNA in sperm, eggs or early embryos to introduce changes that can be inherited.
“Any clinical research...
By Julia Black and Margaux MacColl, The Information [cites CGS' Katie Hasson] | 07.19.2024
When venture capitalist Jack Abraham first began dating his wife, Gabriella Massamillo, he insisted on one condition: that when they were ready to have children, she’d be willing to conceive using in vitro fertilization. Abraham had lost both his mother...